pramipexole ER

DRUG2 trials

Sponsors

Boehringer Ingelheim, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

FibromyalgiaHIVMajor Depressive DisorderMild Neurocognitive Disorder

Phase 2

Pramipexole ER vs. Placebo in Fibromyalgia

TerminatedNCT00689052

Boehringer IngelheimFibromyalgia

Start: 2008-07-31Updated: 2014-06-09

Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV

SuspendedNCT06705478

National Institute of Allergy and Infectious Diseases (NIAID)HIV, Major Depressive Disorder, Mild Neurocognitive Disorder

Start: 2026-05-17End: 2026-12-02Target: 186Updated: 2026-07-14